By Denny Jacob
Ultragenyx Pharmaceutical shares rose 14% to $38.18 following interim data from ongoing studies.
The stock is down 18% on the year so far.
The biopharmaceutical company disclosed that interim data from a study of UX143, a treatment for Osteogenesis Imperfecta, showed statistically significant decrease in annualized fracture rates following at least six months of treatment.
Other data provided at its analyst day included notice that a study of UX701, a treatment for Wilson disease, found that four of five patients in the lowest-dose cohort showed improvements in tapering standard of care.
“The data we are presenting today show that these investigational therapies are having meaningful clinical effects on difficult diseases with limited or no approved treatments,” said Chief Executive Emil Kakkis.
Write to Denny Jacob at [email protected]
Read the full article here